Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015. The Standalone Annual Audited Financial Results ....
Awaiting price reaction for this filing.
Blueblood Ventures Limited's board, at its May 29, 2025 meeting, approved the standalone audited financial results for the half year and full year ended March 31, 2025. Total revenue rose to Rs 80.08 lakhs from Rs 53.93 lakhs in FY24, but the jump was driven almost entirely by a spike in 'other income' (from Rs 2.78 to Rs 30.06 lakhs) while core revenue from operations stayed nearly flat at Rs 50.02 lakhs (vs Rs 51.15 lakhs). Net profit slumped to just Rs 0.59 lakhs from Rs 2.44 lakhs. Statutory auditor KRA & Associates issued an unmodified/unqualified opinion but flagged three emphasis-of-matter items: Rs 5,656.71 lakhs of unconfirmed advances treated as recoverable, Rs 4,149 lakhs of Zero Optionally Convertible Debentures (of which 247 ZOCDs were 'wrongly transferred' to a third party), and Rs 1.61 lakhs of TDS neither paid nor filed. The balance sheet shows long-term borrowings of Rs 9,400 lakhs against share capital of only Rs 300.11 lakhs, and cash flow from operations was negative at Rs (320.73) lakhs for the second straight year.
Despite a clean audit opinion, the disclosures — particularly the wrongly transferred ZOCDs and the large pool of unconfirmed advances — are red flags worth investor attention. The combination of very high debt versus tiny equity, negative operating cash flows, and razor-thin profitability suggests elevated financial risk for shareholders.